Virtus LifeSci Biotech Clinical Trls ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Virtus LifeSci Biotech Clinical Trials ETF BBC
Morningstar’s Analysis BBC
Will BBC outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 15.6
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Kodiak Sciences Inc | 2.09 | 850,828 | Healthcare |
First Tracks Biotherapeutics Inc | 2.01 | 816,341 | Healthcare |
AbCellera Biologics Inc Ordinary Shares | 1.91 | 776,985 | Healthcare |
Xencor Inc | 1.90 | 771,853 | Healthcare |
Amylyx Pharmaceuticals Inc | 1.51 | 615,525 | Healthcare |
SpyGlass Pharma Inc | 1.31 | 531,758 | Healthcare |
Nurix Therapeutics Inc Ordinary Shares | 1.23 | 499,877 | Healthcare |
Prime Medicine Inc | 1.22 | 497,444 | Healthcare |
SELLAS Life Sciences Group Inc | 1.21 | 493,226 | Healthcare |
Definium Therapeutics Inc Ordinary Shares | 1.17 | 475,440 | Healthcare |